Literature DB >> 9429039

Limits of laryngeal mask airway in patients after cervical or oral radiotherapy.

O Giraud1, J L Bourgain, P Marandas, V Billard.   

Abstract

PURPOSE: To test the efficacy of the LMA in patients with previous oral or cervical radiotherapy, without upper airway obstruction.
METHODS: In nine patients after oral or cervical radiotherapy, efficiency of ventilation was assessed after induction of general anaesthesia and LMA insertion. Fibreoptic examination through the tube was performed to check the position of LMA.
RESULTS: In patients who had had oral radiotherapy, all five had limited mouth opening and in two, LMA insertion was difficult but permitted good ventilation. In the four patients who had had cervical radiotherapy, LMA insertion was easy but, in two, the lungs were difficult to ventilate and, in two, the lungs could not be ventilated and orotracheal intubation was required.
CONCLUSION: In patients with limitation of mouth opening after oral radiotherapy, LMA may represent an alternative to tracheal intubation. In patient with cervical sclerosis after radiotherapy; the use of LMA should be avoided.

Entities:  

Mesh:

Year:  1997        PMID: 9429039     DOI: 10.1007/BF03012769

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  2 in total

1.  Non-conventional emergency airway management.

Authors:  Lar Dhar Mishra; Surya Kumar Dube; Surya Kumar Dubey; Ankit Agarwal; Sujit Kumar Pradhan
Journal:  Clinics (Sao Paulo)       Date:  2010-06       Impact factor: 2.365

2.  The difficult airway with recommendations for management--part 2--the anticipated difficult airway.

Authors:  J Adam Law; Natasha Broemling; Richard M Cooper; Pierre Drolet; Laura V Duggan; Donald E Griesdale; Orlando R Hung; Philip M Jones; George Kovacs; Simon Massey; Ian R Morris; Timothy Mullen; Michael F Murphy; Roanne Preston; Viren N Naik; Jeanette Scott; Shean Stacey; Timothy P Turkstra; David T Wong
Journal:  Can J Anaesth       Date:  2013-10-17       Impact factor: 5.063

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.